PL3347352T3 - Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV - Google Patents
Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIVInfo
- Publication number
- PL3347352T3 PL3347352T3 PL17758388T PL17758388T PL3347352T3 PL 3347352 T3 PL3347352 T3 PL 3347352T3 PL 17758388 T PL17758388 T PL 17758388T PL 17758388 T PL17758388 T PL 17758388T PL 3347352 T3 PL3347352 T3 PL 3347352T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic
- prophylactic
- virus infection
- compounds useful
- hiv virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377312P | 2016-08-19 | 2016-08-19 | |
| US201762457555P | 2017-02-10 | 2017-02-10 | |
| EP17758388.7A EP3347352B1 (en) | 2016-08-19 | 2017-08-17 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| PCT/US2017/047416 WO2018035359A1 (en) | 2016-08-19 | 2017-08-17 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3347352T3 true PL3347352T3 (pl) | 2019-12-31 |
Family
ID=59714166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17758388T PL3347352T3 (pl) | 2016-08-19 | 2017-08-17 | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
| PL19178148.3T PL3597646T3 (pl) | 2016-08-19 | 2017-08-17 | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19178148.3T PL3597646T3 (pl) | 2016-08-19 | 2017-08-17 | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
Country Status (43)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| PL3347352T3 (pl) | 2016-08-19 | 2019-12-31 | Gilead Sciences, Inc. | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
| AR112413A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| US10836746B2 (en) * | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP7038843B2 (ja) | 2018-02-16 | 2022-03-18 | ギリアード サイエンシーズ， インコーポレイテッド | Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体 |
| US20210115061A1 (en) * | 2018-06-21 | 2021-04-22 | Drexel University | Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same |
| KR20230141905A (ko) | 2018-07-16 | 2023-10-10 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| EP3833436A1 (en) * | 2018-08-09 | 2021-06-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3849982A1 (en) | 2018-09-14 | 2021-07-21 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US11919897B2 (en) | 2018-09-20 | 2024-03-05 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| EA202190974A1 (ru) * | 2018-10-22 | 2022-02-02 | Борд Оф Риджентс Оф Зэ Юниверсити Оф Небраска | Противовирусные пролекарства и их наносоставы |
| ES2971987T3 (es) * | 2018-10-24 | 2024-06-10 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| BR112021007362A2 (pt) | 2018-10-24 | 2021-07-20 | VIIV Healthcare UK (No.5) Limited | inibidores da replicação do vírus da imunodeficiência humana |
| US20210393633A1 (en) | 2018-10-25 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20210403465A1 (en) * | 2018-10-29 | 2021-12-30 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| EP3876942A1 (en) | 2018-11-05 | 2021-09-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2020095177A1 (en) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| MX2021008751A (es) | 2019-01-25 | 2021-11-12 | Univ Brown | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad. |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| TW202544011A (zh) | 2019-03-22 | 2025-11-16 | 美商基利科學股份有限公司 | 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途 |
| WO2020222108A1 (en) | 2019-04-30 | 2020-11-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| HUE065762T2 (hu) * | 2019-06-19 | 2024-06-28 | Viiv Healthcare Uk No 5 Ltd | Pirido[2,3-d]pirimidin-származékok mint a humán immunhiányos vírus replikációjának gátlói |
| US20220389007A1 (en) | 2019-10-01 | 2022-12-08 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2021064570A1 (en) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| EP4041729B1 (en) | 2019-10-08 | 2023-09-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2021108544A1 (en) * | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥 |
| TW202128660A (zh) * | 2019-11-29 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合吡啶環衍生物、其製備方法及其在醫藥上的應用 |
| CN113304166B (zh) * | 2020-02-27 | 2022-10-14 | 河南真实生物科技有限公司 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
| US20230106880A1 (en) | 2020-03-06 | 2023-04-06 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| IL296182A (en) | 2020-03-06 | 2022-11-01 | Viiv Healthcare Uk No 5 Ltd | Inhibitors of human immunodeficiency virus replication |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| CN115397424A (zh) | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20220144923A1 (en) | 2020-11-11 | 2022-05-12 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| US11890297B2 (en) | 2021-01-25 | 2024-02-06 | Brii Biosciences, Inc. | Combination therapy for HIV with adenosine derivative and capsid inhibitors |
| WO2022247942A1 (zh) * | 2021-05-28 | 2022-12-01 | 江苏恒瑞医药股份有限公司 | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 |
| KR20230018690A (ko) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물 |
| KR20230019059A (ko) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물 |
| CA3234219A1 (en) * | 2021-10-13 | 2023-04-20 | Gautam Dalwadi | Inhibitors of human immunodeficiency virus replication |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| CN118369316A (zh) * | 2021-12-03 | 2024-07-19 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) * | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| KR20240061218A (ko) | 2022-10-31 | 2024-05-08 | 주식회사 이보드 | 복합 단열재 및 제조방법 |
| IL322370A (en) | 2023-01-30 | 2025-09-01 | Merck Sharp & Dohme Llc | Prodrugs of 4'-modified nucleosides as reverse transcriptase inhibitors |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| WO2024249573A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| US20250011353A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Process of preparing hiv capsid inhibitor |
| CN116675675A (zh) * | 2023-06-05 | 2023-09-01 | 北京康立生医药技术开发有限公司 | 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法 |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| AU2023460182A1 (en) | 2023-07-28 | 2026-02-05 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| EP4529922A1 (en) | 2023-09-29 | 2025-04-02 | Gilead Sciences, Inc. | Pharmaceutical formulations of bictegravir and lenacapavir |
| TW202513072A (zh) | 2023-08-15 | 2025-04-01 | 美商基利科學股份有限公司 | 比替拉韋及利那卡帕韋之醫藥配方 |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| KR20250040288A (ko) | 2023-09-15 | 2025-03-24 | 민영호 | 복합 단열재 |
| WO2025080879A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025240389A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240391A2 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367381A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367385A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367384A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025264995A1 (en) * | 2024-06-21 | 2025-12-26 | Gilead Sciences, Inc. | Formulations of an hiv capsid inhibitor |
| WO2026006521A1 (en) | 2024-06-27 | 2026-01-02 | Gilead Sciences, Inc. | Oral tablet formulations |
| WO2026020086A1 (en) | 2024-07-19 | 2026-01-22 | Gilead Sciences, Inc. | Methods and pharmaceutical formulations for treating viral infections |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ATE131825T1 (de) | 1990-06-13 | 1996-01-15 | Arnold Glazier | Phosphorylierte prodrugs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU8294101A (en) | 2000-07-21 | 2002-02-05 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| DE60223920T2 (de) | 2001-06-27 | 2008-11-13 | Smithkline Beecham Corp. | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
| SI1441734T1 (sl) | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| US20040186151A1 (en) | 2003-02-12 | 2004-09-23 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
| US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| EP1737881B1 (en) | 2004-02-27 | 2009-06-24 | Schering Corporation | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| HRP20070078A2 (hr) | 2004-07-27 | 2007-05-31 | Gilead Sciences | Fosfonatni analozi spojeva koji inhibiraju hiv |
| US8067587B2 (en) | 2005-07-28 | 2011-11-29 | Lenroc Company | Process for the production of monoalkali metal cyanurates |
| AU2006279034A1 (en) | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| JP5225098B2 (ja) | 2005-12-14 | 2013-07-03 | ブリストル−マイヤーズ スクイブ カンパニー | 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ |
| EP2010493B1 (en) | 2006-04-12 | 2016-01-27 | Merck Sharp & Dohme Corp. | Pyridyl amide t-type calcium channel antagonists |
| US7647464B2 (en) | 2006-04-28 | 2010-01-12 | At&T Intellectual Property, I,L.P. | Methods, systems, and products for recording media to a restoration server |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| CA2681718A1 (en) | 2007-03-23 | 2008-10-02 | University Of Massachusetts | Hiv-1 protease inhibitors |
| EA200971074A1 (ru) | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | Антивирусные соединения |
| HRP20131128T1 (hr) | 2007-07-12 | 2013-12-20 | Janssen R&D Ireland | Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila |
| JP5433573B2 (ja) | 2007-07-19 | 2014-03-05 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 抗ウイルス剤としての大環状化合物 |
| JP5524071B2 (ja) | 2007-10-24 | 2014-06-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト |
| US20100249176A1 (en) | 2007-10-24 | 2010-09-30 | Barrow James C | Heterocycle amide t-type calcium channel antagonists |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| ATE543811T1 (de) | 2008-03-13 | 2012-02-15 | Bristol Myers Squibb Co | Pyridazinderivate als faktor-xia-inhibitoren |
| SG172060A1 (en) | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
| EP2401286A4 (en) | 2009-02-25 | 2012-09-26 | Bigtec Private Ltd | PROBES AND PRIMERS FOR DETECTION OF CHIKUNGUNYA |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| CA2802492C (en) | 2010-07-02 | 2018-10-16 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| ES2634490T3 (es) | 2010-07-02 | 2017-09-28 | Gilead Sciences, Inc. | Derivados de ácido napht-2-ylacetico para tratar el sida |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PL3290415T3 (pl) | 2011-03-23 | 2021-07-19 | Trevena, Inc. | Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania |
| AP2013007249A0 (en) | 2011-04-21 | 2013-11-30 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| SMT201600476T1 (it) | 2011-08-16 | 2017-03-08 | Gilead Sciences Inc | Tenofovir alafenammide emifumarato |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| PH12014500842A1 (en) | 2012-04-20 | 2014-06-09 | Gilead Sciences Inc | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| PE20151499A1 (es) | 2012-12-21 | 2015-10-29 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico |
| WO2014104279A1 (ja) | 2012-12-27 | 2014-07-03 | 日本たばこ産業株式会社 | 置換されたスピロピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| AU2014205317B2 (en) | 2013-01-09 | 2016-11-24 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| TWI706945B (zh) * | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| WO2015061518A1 (en) | 2013-10-24 | 2015-04-30 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| CA2958742C (en) * | 2014-08-29 | 2019-04-30 | Gilead Sciences, Inc. | Antiretroviral agents |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| EP3237414B1 (en) | 2014-12-24 | 2019-05-08 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the tratment of hiv |
| EP3286174A1 (en) | 2015-04-23 | 2018-02-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| AU2016250661B2 (en) | 2015-04-23 | 2018-07-26 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| SI3191470T1 (sl) * | 2015-07-06 | 2019-04-30 | Gilead Sciences, Inc. | Modulatorji COT in postopki njihove uporabe |
| US10171985B1 (en) | 2015-07-22 | 2019-01-01 | Ginko LLC | Method and apparatus for data sharing |
| PL3347352T3 (pl) | 2016-08-19 | 2019-12-31 | Gilead Sciences, Inc. | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP7038843B2 (ja) | 2018-02-16 | 2022-03-18 | ギリアード サイエンシーズ， インコーポレイテッド | Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体 |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| KR20230141905A (ko) | 2018-07-16 | 2023-10-10 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| WO2021108544A1 (en) | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
-
2017
- 2017-08-17 PL PL17758388T patent/PL3347352T3/pl unknown
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/pl unknown
- 2017-08-17 KR KR1020257017413A patent/KR20250085838A/ko active Pending
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/fi active
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/en not_active Ceased
- 2017-08-17 HK HK18116015.7A patent/HK1256904B/en unknown
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/hu unknown
- 2017-08-17 UY UY0001037367A patent/UY37367A/es not_active Application Discontinuation
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/pt active Search and Examination
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/ko not_active Ceased
- 2017-08-17 MA MA050673A patent/MA50673A/fr unknown
- 2017-08-17 KR KR1020247014103A patent/KR20240070646A/ko not_active Ceased
- 2017-08-17 PH PH1/2021/552802A patent/PH12021552802A1/en unknown
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/hr unknown
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/hu unknown
- 2017-08-17 UA UAA201901739 patent/UA121630C2/uk unknown
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/ja active Active
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/ko active Active
- 2017-08-17 CN CN202411603090.3A patent/CN119462611A/zh active Pending
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/da active
- 2017-08-17 SI SI201730077T patent/SI3347352T1/sl unknown
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 MX MX2018012905A patent/MX369307B/es active IP Right Grant
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 CR CR20190084A patent/CR20190084A/es unknown
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/en active Active
- 2017-08-17 TW TW113111532A patent/TW202504608A/zh unknown
- 2017-08-17 PT PT17758388T patent/PT3347352T/pt unknown
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/zh active Active
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/en active Pending
- 2017-08-17 TW TW109146483A patent/TW202138365A/zh unknown
- 2017-08-17 CN CN202010662665.4A patent/CN111793061B/zh active Active
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/ko not_active Ceased
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/da active
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/es unknown
- 2017-08-17 TW TW108108262A patent/TWI715944B/zh active
- 2017-08-17 PT PT191781483T patent/PT3597646T/pt unknown
- 2017-08-17 ES ES17758388T patent/ES2746374T3/es active Active
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/lt unknown
- 2017-08-17 TW TW106127987A patent/TWI664966B/zh active
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 TW TW112100805A patent/TWI853404B/zh active
- 2017-08-17 ES ES19178148T patent/ES2954514T3/es active Active
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/en active Active
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/pt active IP Right Grant
- 2017-08-17 SI SI201731404T patent/SI3597646T1/sl unknown
- 2017-08-17 MA MA42795A patent/MA42795B1/fr unknown
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/es unknown
- 2017-08-17 CA CA3021227A patent/CA3021227C/en active Active
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/lt unknown
-
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/ar unknown
-
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/es unknown
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/es unknown
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/es unknown
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/es unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/ar unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/el unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
-
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/ja not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/ja active Pending
-
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
-
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/ja not_active Withdrawn
- 2022-12-13 LU LU00292C patent/LUC00292I2/fr unknown
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/hu unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/fr active Active
- 2022-12-16 NO NO2022059C patent/NO2022059I1/no unknown
- 2022-12-22 CY CY2022039C patent/CY2022039I1/el unknown
-
2023
- 2023-01-05 LT LTPA2023501C patent/LTC3347352I2/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/nl unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739B2/en active Active
-
2024
- 2024-04-11 US US18/632,593 patent/US20240376077A1/en active Pending
- 2024-08-30 JP JP2024148326A patent/JP2024170471A/ja active Pending
-
2025
- 2025-11-21 AU AU2025271141A patent/AU2025271141A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901430B (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| IL284255A (en) | 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection | |
| IL246449A0 (en) | 6-compressed new heteroaryldihydropyrimidines for the treatment and prevention of hepatitis b virus infection | |
| IL280769A (en) | New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection | |
| IL245436A0 (en) | New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection | |
| PT3519569T (pt) | Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses | |
| EP3137078A4 (en) | Treatment of hepatitis delta virus infection | |
| EP3226973A4 (en) | Treatment of hepatitis delta virus infection | |
| EP3448377A4 (en) | METHODS FOR THE TREATMENT OF AN INFECTION | |
| ZA201900770B (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| LT3504210T (lt) | Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai | |
| HK40006685A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| HK40005971A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |